Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27961324 | 0.88 | ALDH1A1 (0.32) | ALDH1A1TSHRPOLB | |
| SCHEMBL24112327 | 0.85 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBMAPTAURKA | |
| SCHEMBL4369849 | 0.85 | ALDH1A1 (0.35) | ALDH1A1TSHRPOLBMAPT | |
| SCHEMBL27735915 | 0.85 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBAURKA | |
| SCHEMBL3844719 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHRPOLBMAPTAURKA | |
| SCHEMBL27961325 | 0.78 | P2RX7 (0.36) | ALDH1A1TSHRPOLBAURKA | |
| SCHEMBL34473961 | 0.76 | POLB (0.40) | ALDH1A1TSHRPOLBMAPTAURKA | |
| SCHEMBL22405796 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TSHRPOLBAURKA | |
| SCHEMBL16211997 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TSHRAURKA | |
| SCHEMBL3852012 | 0.73 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBMAPTAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991987-B1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9505762-B2 | Purine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-11-29 | — | — | US | disclosed |
| CN-104039791-B | [1, 2, 3] triazolo [4, 5-D ] pyrimidine derivatives as cannabinoid receptor 2 agonists | 霍夫曼-拉罗奇有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-103930426-B | As [1,2,3] triazols [4, the 5-D] pyrimidine derivatives of Cannabined receptor 2 activators | HOFFMAN-LA ROCHE LTD. (CH) | 2016-05-11 | — | — | CN | disclosed |
| EP-2991987-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2776442-B1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9056866-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1924563-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | ALDH1A1 105/4885TSHR 2784/4885POLB 1084/4885 |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | CNR1, CNR2, P2RY1 | ALDH1A1 1306/4885TSHR 450/4885POLB 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.